Sugi Predict

Sugi Predict / Compounds / SCHEMBL18151052

SCHEMBL18151052

SCHEMBL18151052

c1ccc([C@H]2COCc3nc4ccc(-c5cnc(N6CCC7(COC7)C6)nc5)cc4n32)cc1

nearest known ligand 0.33

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ TNF P01375 3/20 0.33
▸ TTK P33981 2/20 0.33
▸ MAOB P27338 2/20 0.33
▸ HTR6 P50406 2/20 0.33
▸ DYRK1A Q13627 1/20 0.32
▸ MAP3K12 Q12852 2/20 0.32
▸ CCNC P24863 1/20 0.31
▸ CDK8 P49336 1/20 0.31
▸ CYP11B1 P15538 1/20 0.31
▸ CYP11B2 P19099 1/20 0.31
▸ NAMPT P43490 2/20 0.31
▸ DGAT1 O75907 1/20 0.31
▸ BRD4 O60885 2/20 0.31
▸ CNR2 P34972 1/20 0.31
▸ HDAC1 Q13547 1/20 0.31
▸ HDAC8 Q9BY41 1/20 0.31
▸ HDAC6 Q9UBN7 1/20 0.31
▸ HDAC5 Q9UQL6 1/20 0.31
▸ AOC3 Q16853 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18150982 0.95 TNF (0.34) TNFMAP3K12CCNCCDK8CYP11B1
SCHEMBL18151991 0.91 TNF (0.35) TNFCCNCCDK8AOC3
SCHEMBL18151185 0.87 TNF (0.33) TNFCCNCCDK8DGAT1BRD4
SCHEMBL18150965 0.87 TNF (0.36) TNFBRD4HDAC1HDAC8HDAC6
SCHEMBL18159823 0.86 TNF (0.35) TNFCCNCCDK8BRD4AOC3
SCHEMBL18151375 0.86 AOC3 (0.43) TNFCNR2AOC3
SCHEMBL18150795 0.86 AOC3 (0.43) TNFCNR2AOC3
SCHEMBL18150738 0.86 AOC3 (0.43) TNFCNR2AOC3
SCHEMBL18151022 0.85 TNF (0.37) TNFDGAT1
SCHEMBL18151021 0.85 TNF (0.34) TNFBRD4AOC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3288939-A1 TRICYCLIC MODULATORS OF TNF SIGNALING AbbVie Inc. (US) 2018-03-07 — — EP claimed
US-20160304517-A1 TRICYCLIC MODULATORS OF TNF SIGNALING ABBVIE INC. 2016-10-20 — — US claimed
WO-2016168641-A1 TRICYCLIC MODULATORS OF TNF SIGNALING ABBVIE INC. (US) 2016-10-20 — — WO claimed
US-20260131007-A1 Mannose 6-Phosphate Receptor Binding Compounds for the Degradation of Extracellular Proteins AVILAR THERAPEUTICS, INC. (US) 2026-05-14 — — US disclosed
US-20260083851-A1 POTENT ASGPR-BINDING HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS AVILAR THERAPEUTICS, INC. (US) 2026-03-26 — — US disclosed
US-20250269043-A1 TARGETED BIFUNCTIONAL DEGRADERS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2025-08-28 — — US disclosed
EP-4493221-A2 TARGETED BIFUNCTIONAL DEGRADERS Yale University (US) 2025-01-22 — — EP disclosed
CN-119212727-A Targeted bifunctional degradants 耶鲁大学 2024-12-27 — — CN disclosed
WO-2024182772-A2 MANNOSE 6-PHOSPHATE RECEPTOR BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS AVILAR THERAPEUTICS, INC. (US) 2024-09-06 — — WO disclosed
WO-2024098039-A2 POTENT ASGPR-BINDING HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS AVILAR THERAPEUTICS, INC. (US) 2024-05-10 — — WO disclosed
WO-2023178199-A2 TARGETED BIFUNCTIONAL DEGRADERS YALE UNIVERSITY (US) 2023-09-21 — — WO disclosed
US-20180179198-A1 TRICYCLIC MODULATORS OF TNF SIGNALING ABBVIE INC. 2018-06-28 — — US disclosed
EP-3288939-A1 TRICYCLIC MODULATORS OF TNF SIGNALING AbbVie Inc. (US) 2018-03-07 — — EP disclosed
US-9856253-B2 Tricyclic modulators of TNF signaling ABBVIE, INC. (US) 2018-01-02 — — US disclosed
US-9856253-B2 Tricyclic modulators of TNF signaling ABBVIE, INC. (US) 2018-01-02 — — US disclosed
US-20160304517-A1 TRICYCLIC MODULATORS OF TNF SIGNALING ABBVIE INC. 2016-10-20 — — US disclosed
WO-2016168641-A1 TRICYCLIC MODULATORS OF TNF SIGNALING ABBVIE INC. (US) 2016-10-20 — — WO disclosed
US-20160304517-A1 TRICYCLIC MODULATORS OF TNF SIGNALING ABBVIE INC. 2016-10-20 — — US disclosed
WO-2016168641-A1 TRICYCLIC MODULATORS OF TNF SIGNALING ABBVIE INC. (US) 2016-10-20 — — WO disclosed
US-20160304517-A1 TRICYCLIC MODULATORS OF TNF SIGNALING ABBVIE INC. 2016-10-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250269043-A1 TARGETED BIFUNCTIONAL DEGRADERS SMURF2, SMURF1, MDM2 TNF 5/4885TTK 863/4885MAOB 1192/4885
US-20260083851-A1 POTENT ASGPR-BINDING HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS ASGR1, FCGR2A, FCGR3B TNF 4166/4885TTK 3466/4885MAOB 2984/4885
US-20160304517-A1 TRICYCLIC MODULATORS OF TNF SIGNALING TNF, TNFRSF1A, CD40 TNF 1/4885TTK 1507/4885MAOB 2977/4885
US-20260131007-A1 Mannose 6-Phosphate Receptor Binding Compounds for the Degradation of Extracellular Proteins IGF2R, M6PR, MSR1 TNF 4238/4885TTK 3556/4885MAOB 3288/4885
US-20180179198-A1 TRICYCLIC MODULATORS OF TNF SIGNALING TNF, TNFRSF1A, CD40 TNF 1/4885TTK 1507/4885MAOB 2977/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.